bluebird bio, Inc. (BLUE): Price and Financial Metrics

BLUE POWR Grades

• Growth is the dimension where BLUE ranks best; there it ranks ahead of 87.5% of US stocks.
• BLUE's strongest trending metric is Momentum; it's been moving up over the last 178 days.
• BLUE's current lowest rank is in the Stability metric (where it is better than 0.51% of US stocks).

BLUE Stock Summary

• BLUEBIRD BIO INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.17% of US listed stocks.
• With a year-over-year growth in debt of 53.23%, BLUEBIRD BIO INC's debt growth rate surpasses 81.07% of about US stocks.
• Revenue growth over the past 12 months for BLUEBIRD BIO INC comes in at -166.63%, a number that bests only 0.33% of the US stocks we're tracking.
• Stocks that are quantitatively similar to BLUE, based on their financial statements, market capitalization, and price volatility, are LYEL, SNAP, SITM, RKLB, and AI.
• Visit BLUE's SEC page to see the company's official filings. To visit the company's web site, go to www.bluebirdbio.com.

BLUE Valuation Summary

• In comparison to the median Healthcare stock, BLUE's price/sales ratio is 980% lower, now standing at -17.6.
• BLUE's EV/EBIT ratio has moved up 11.3 over the prior 115 months.

Below are key valuation metrics over time for BLUE.

BLUE Growth Metrics

Its 5 year revenue growth rate is now at 778.41%.
• Its 3 year price growth rate is now at -97.68%.
• Its year over year revenue growth rate is now at -102.97%.

BLUE's revenue has moved down $71,433,000 over the prior 52 months.

The table below shows BLUE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	-35.746	-436.405	-453.862
2022-06-30	-13.14	-506.318	-594.158
2022-03-31	-7.187	-557.608	-735.722
2021-12-31	3.662	-635.639	-819.378
2021-09-30	53.651	-651.107	-864.2
2021-06-30	50.247	-652.948	-842.129

BLUE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• BLUE has a Quality Grade of D, ranking ahead of 15.84% of graded US stocks.
• BLUE's asset turnover comes in at 0.029 -- ranking 353rd of 682 Pharmaceutical Products stocks.
• NERV, OTLC, and BPMC are the stocks whose asset turnover ratios are most correlated with BLUE.

The table below shows BLUE's key quality metrics over time.